Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.25% | 13.65% | 9.63% | -8.05% | -9.52% |
| Total Depreciation and Amortization | 21.91% | 16.34% | 10.42% | -1.06% | -0.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 319.88% | 346.48% | 6.93% | -102.04% | -132.43% |
| Change in Net Operating Assets | -298.22% | -209.99% | -226.40% | -221.60% | 1,363.61% |
| Cash from Operations | -18.41% | -33.80% | -44.56% | -56.08% | -44.83% |
| Capital Expenditure | -450.65% | -269.49% | -41.96% | -15.42% | 38.23% |
| Sale of Property, Plant, and Equipment | -97.89% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -775.88% | -229.26% | -2.45% | -100.49% | -100.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.54% | -14,078.69% | -11,408.06% | -9,066.87% | -3,512.00% |
| Issuance of Common Stock | -18.02% | -27.10% | 159.57% | 4.35% | 565.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -20.45% | -47.69% | 117.20% | -36.53% | 499.78% |
| Foreign Exchange rate Adjustments | -69.46% | -543.33% | -338.01% | 113.24% | 16.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -139.92% | -138.46% | 1,175.93% | -184.82% | 105.68% |